BMS, Innate say no plans to table lirilumab just yet

Innate Pharma S.A. (Euronext:IPH) confirmed that discussions with partner Bristol-Myers Squibb Co. (NYSE:BMY) remain ongoing regarding next steps for cancer compound lirilumab (BMS-986015, IPH2102). In

Read the full 250 word article

User Sign In